Toxoplasmosis Treatment Market Size & Share, by Route of Administration (Oral, Intravenous); End user; Distribution Channel; Drug Class; Indication; Type; Population - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2026-2035

Toxoplasmosis Treatment Market - Regional Analysis

North America Market Insights

North America in the market is projected to emerge as the most dominating region by accounting for the largest market share of 38.6% by the end of 2035. The market’s exposure in the region is highly attributed to an increase in HIV and AIDS prevalence, stringent prenatal screening reforms, robust research and development (R&D) activities in pharmacy, and innovative healthcare facilities. As per a report published by Genetics in Medicine in February 2023, noninvasive prenatal screening has been useful for detecting NT sonogram during first trimester within a range of 64% to 70%, followed by 82% to 87% for NT and serum analytes, and 69% for maternal serum AFP, thereby suitable for the market’s growth.

The market in the U.S. is steadily growing, owing to an expansion in Medicaid and Medicare services, FDA-approved drugs, an increase in the immunocompromised population, and private insurance reimbursement policies. Besides, the June 2023 NLM article reported that over 2.8 million antibiotic-resistant infections occur every year, and over 35,000 people die due to this condition. Besides, the August 2024 MACPRAC report denoted that Medicaid tends to lower unnecessary expenses, which range between USD 600 billion to more than USD 1.9 trillion every year, thereby managing them wisely in the country’s healthcare system.

The market in Canada is also growing due to the presence of provincial universal healthcare, neonatal screening reforms, biosimilar integration, and government investment.  According to the March 2025 Government of Canada report, the Infectious Disease and Climate Change Fund made an investment of USD 520,248 to the Acadia University to assess the expansion in mosquito and vector potential range between April 2020 and March 2025. Likewise, the regulatory body funded USD 1,263,080 to Bishop’s University for ensuring citizen-based Ixodes scapularis surveillance between September 2018 to March 2024. Therefore, with such fund provision from the government, there is a huge opportunity for the market to flourish.

HIV Incidences in North America

Sources: CDC, April 2024; Government of Canada, December 2023

APAC Market Insights

Asia Pacific in the toxoplasmosis treatment market is projected to be the fastest-growing region by garnering a share of 22.4% by the end of the forecast duration. The market’s upliftment in the region is propelled by a surge in seroprevalence rates, a rise in the immunocompromised population, improved diagnostic capabilities, and harmonization of drug approvals. As per an article published by Science for Optimal Cancer Care in February 2024, 78.5% of distal and 62.1% of proximal gastric cancer are attributed to H. pylori infection. In addition, the H. pylori prevalence in distal GC cases in China was 66.5%, thereby denoting a huge demand for the market in the region.

The market in China is significantly growing, owing to the existence of the Health China 2030 initiative by the central government, massive regional pharmaceutical manufacturing, and an expansion in public health insurance. According to the April 2022 NLM article, the duration for including innovative drugs in the National Reimbursement Drug List (NRDL) has been reduced from 4 to 5 years to within the clearance year. Besides, the Center for Drug Evaluation (CDE) introduced 100 new drugs as of 2022 through R&D consultations and guidelines. Meanwhile, the proportion of domestic new drugs applying for their first IND was 79% in the same year, thus suitable for the market’s growth.

The market in India is also growing due to generic dominance, increase in cost sensitivity, fragmentation in the public health system, and pioneering role in the WHO’s prequalified generic manufacturing. As per the June 2025 PIB report, the Ayushman Bharat- Pradhan Mantri Jan Arogya Yojana (PM-JAY) scheme has created 41.0 crore (410 million) health cards, along with treatments worth ₹1.19 crore (USD 136,767), health coverage of ₹5 lakhs (USD 5,747) for per family every year, and the presence of 31,958 hospitals. Therefore, with such facilities and developments, the market is expected to gain increased exposure in the overall country.

Europe Market Insights

Europe in the toxoplasmosis treatment market is projected to account for a considerable share of 28.4% during the forecast timeline. The market’s development in the region is highly driven by the presence of a centralized EMA administrative pathway, health programme funding facilities, harmonized clinical policies, and increased cross-border healthcare mobility. According to the August 2025 European Commission report, the HaDEA successfully published the EU4Health call for tenders to effectively implement digital health strategies, with an indicated budget accounting for €1,000,000. This also includes operations related to the European Health Data Space (EHDS) Regulation, thereby catering to the market’s growth in the region.

The market in Germany is steadily growing, owing to the presence of the Federal Joint Committee (G-BA) and early benefit assessment (AMNOG), robust organ drug incentives, and decentralized hospital formulary decisions (G-DRG). As per the December 2024 NLM article, the rare disease prevalence in Europe Union is more than or equal to 5 per 10,000 population, due to which 63 orphan drugs have been approved. In addition, the German Act on the Reform of the Market for Medicinal Products was formed, and newly cleared orphan drugs underwent an early benefit assessment under the act.

The toxoplasmosis treatment market in France is also growing due to compulsory nationwide prenatal screening law, the presence of a transparency committee and ASMR rating system, along with standard research institutes. According to the May 2023 NLM article, almost 800,000 children are screened every year, including 32,500 in Brittany. Generally, neonatal screening takes place between 48 hours and 72 hours of life. Besides, French neonatal screening assists in detecting sickle cell disease, congenital adrenal hyperplasia, phenylketonuria, and cystic fibrosis, thereby suitable for the overall market’s exposure.

Measuring or Checking Equipment 2023 Export and Import Data

Source: OEC, May 2025